Generation of Neutralizing Monoclonal Antibodies against a Conformational Epitope of Human Adenovirus Type 7 (HAdv-7) Incorporated in Capsid Encoded in a HAdv-3-Based Vector
The generation of monoclonal antibodies (MAbs) by epitope-based immunization is difficult because the immunogenicity of simple peptides is poor and T cells must be potently stimulated and immunological memory elicited. A strategy in which antigen is incorporated into the adenoviral capsid protein has been used previously to develop antibody responses against several vaccine targets and may offer a solution to this problem. In this study, we used a similar strategy to develop HAdv-7-neutralizing MAbs using rAdMHE3 virions into which hexon hypervariable region 5 (HVR5) of adenovirus type 7 (HAdv-7) was incorporated. The epitope mutant rAdMHE3 was generated by replacing HVR5 of Ad3EGFP, a recombinant HAdv-3-based vector expressing enhanced green fluorescence protein, with HVR5 of HAdv-7. We immunized BALB/c mice with rAdMHE3 virions and produced 22 different MAbs against them, four of which showed neutralizing activity against HAdv-7 in vitro. Using an indirect enzyme-linked immunosorbent assay (ELISA) analysis and an antibody-binding-competition ELISA with Ad3EGFP, HAdv-7, and a series of chimeric adenoviral particles containing epitope mutants, we demonstrated that the four MAbs recognize the neutralization site within HVR5 of the HAdv-7 virion. Using an immunoblotting analysis and ELISA with HAdv-7, recombinant peptides, and a synthetic peptide, we also showed that the neutralizing epitope within HVR5 of the HAdv-7 virion is a conformational epitope. These findings suggest that it is feasible to use a strategy in which antigen is incorporated into the adenoviral capsid protein to generate neutralizing MAbs. This strategy may also be useful for developing therapeutic neutralizing MAbs and designing recombinant vector vaccines against HAdv-7, and in structural analysis of adenoviruses.
References
[1]
Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461–470. doi: 10.1016/s0952-7915(03)00083-9
[2]
Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16: 3149–3157. doi: 10.2174/138161210793292447
[3]
Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404–414. doi: 10.1038/nrd2224
[4]
Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75: 133–139. doi: 10.1099/0022-1317-75-1-133
[5]
Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281–1289. doi: 10.1172/jci200523135
[6]
Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, et al. (2001) Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 61: 7913–7919.
[7]
Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, et al. (2004) Modification to the capsid of the adenovirus vector that enhance dendritic cell infection and transgene-specific cellular immune response. J Virol 78: 2572–2580. doi: 10.1128/jvi.78.5.2572-2580.2004
[8]
Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523–5530. doi: 10.1128/jvi.02667-05
[9]
Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688–3701. doi: 10.1172/jci39812
[10]
Dittmer U, Brooks DM, Hasenkrug KJ (1998) Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol 72: 6554–6558.
[11]
Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815. doi: 10.1371/journal.pone.0011815
[12]
Matthews QL (2011) Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3–11. doi: 10.1021/mp100214b
[13]
Yang Y, Li Q, Ertl HC, Wilson JM (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004–2015.
[14]
Jooss K, Chirmule N (2003) Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 10: 955–963. doi: 10.1038/sj.gt.3302037
[15]
Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461–470. doi: 10.1016/s0952-7915(03)00083-9
[16]
Zhang Q, Su X, Seto D, Zheng BJ, Tian X, et al. (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27: 1145–1153. doi: 10.1016/j.vaccine.2008.12.039
[17]
Tian X, Su X, Li X, Li H, Li T, et al. (2012) Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon. PLoS One 7: e41381. doi: 10.1371/journal.pone.0041381
[18]
Qiu H, Li X, Tian X, Zhou Z, Xing K, et al. (2012) Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol 86: 7964–7975. doi: 10.1128/jvi.07076-11
[19]
Tian X, Su X, Li H, Zhou Z, Liu W, et al. (2011) Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res 160: 214–220. doi: 10.1016/j.virusres.2011.06.017
[20]
Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775–12782. doi: 10.1128/jvi.76.24.12775-12782.2002
[21]
Choi EH, Kim HS, Park KH, Lee HJ (2006) Genetic heterogeneity of the hexon gene of adenovirus type 3 over a 9-year period in Korea. J Med Virol 78: 379–383. doi: 10.1002/jmv.20550
[22]
Xu ZK (1992) Shi yong dan ke long ji shu. Xi’an: Shanxi Science and Technology Press. 124 p.
[23]
Tian X, Li C, Xue C, Li X, Zhou Z, et al. (2013) Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3. Virus Res 177: 189–193. doi: 10.1016/j.virusres.2013.08.013
[24]
Fortsas E, Petric M, Brown M (1994) Electrophoretic migration of adenovirus hexon under non-denaturing conditions. Virus Res 31: 57–65. doi: 10.1016/0168-1702(94)90071-x
[25]
Desoubeaux G, Daquet A, Watier H (2013) Therapeutic antibodies and infectious disease, Tours, France, November 20–22, 2012. MAbs 5: 626–632. doi: 10.4161/mabs.25300
[26]
Berry JD, Gaudet RG (2011) Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol 28: 489–501. doi: 10.1016/j.nbt.2011.03.018
[27]
Herbert WJ (1978) Mineral oil adjuvants and the immunization of laboratory animals. In: Weir DM;editors. Handbook of Experimental Immunology, 3rd ed. Oxford: Blackwell Scientific Publications.
[28]
Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ (2000) Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther 11: 759–769. doi: 10.1089/10430340050015653
[29]
Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, et al. (2001) Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3: 697–707. doi: 10.1006/mthe.2001.0329
[30]
Yu P, Ma C, Nawaz M, Han L, Zhang J, et al. (2013) Outbreak of acute respiratory disease caused by human adenovirus type 7 in a military training camp in Shaanxi, China. Microbiol Immunol 57: 553–560. doi: 10.1111/1348-0421.12074
[31]
Tang L, Wang L, Tan X, Xu W (2011) Adenovirus serotype 7 associated with a severe lower respiratory tract disease outbreak in infants in Shaanxi Province, China. Virol J 8: 23. doi: 10.1186/1743-422x-8-23
[32]
Tsou TP, Tan BF, Chang HY, Chen WC, Huang YP, et al. (2012) Community Outbreak of Adenovirus, Taiwan, 2011. Emerg Infect Dis 18: 1825–1832. doi: 10.3201/eid1811.120629
[33]
Lai CY, Lee CJ, Lu CY, Lee PI, Shao PL, et al. (2013) Adenovirus serotype 3 and 7 infection with acute respiratory failure in children in Taiwan, 2010–2011. PLoS One 8: e53614. doi: 10.1371/journal.pone.0053614
[34]
Guo L, Gonzalez R, Zhou H, Wu C, Vernet G, et al. (2012) Detection of three human adenovirus species in adults with acute respiratory infection in China. Eur J Clin Microbiol Infect Dis 31: 1051–1058. doi: 10.1007/s10096-011-1406-8
